Journals / Türk Osteoporoz Dergisi / 2018 / Cilt: 24 - Sayı: 1

A Case of Chronic Gouty Arthritis with Atypical Localized Tophi

Atipik Yerleşimli Tofüslerle Seyreden Bir Kronik Gut Artriti Olgusu

Pages
26–28
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In conclusion, it should be kept in mind to clinical practice that in chronic cases, tophi may localized in atypical regions other than classical localizations, and tophus may lead to joint destruction due to delayed treatment.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Gout disease is an inflammatory disease triggered by monosodium urate monohydrate crystals that accumulate in tissues due to hyperuricemia, which usually seen in males over 40 years.
📊
Key Findings & Data:In the patient who started colchicine 1 mg/day and allopurinol 300 mg/day, the joint pain improved and the tofus in the ear helix disappeared completely at the 6th month control.
💡
Conclusion & Impact:In conclusion, it should be kept in mind to clinical practice that in chronic cases, tophi may localized in atypical regions other than classical localizations, and tophus may lead to joint destruction due to delayed treatment.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Gout disease is an inflammatory disease triggered by monosodium urate monohydrate crystals that accumulate in tissues due to hyperuricemia, which usually seen in males over 40 years. Chronic obstructive polyarthritis and chronic gouty arthritis coursing with tophi may develop in patients who are not adequately treated. Tophi are frequently observed in hand-foot fingers, olecranon bursa, prepatellar bursa, ear helix and achilles tendon. As for that in our case, tophi were present in bilateral lumbar paravertebral muscles and left cervical paravertebral muscles in addition to hand-foot joints, ear helix and olecranon bursa. In the patient who started colchicine 1 mg/day and allopurinol 300 mg/day, the joint pain improved and the tofus in the ear helix disappeared completely at the 6th month control. In conclusion, it should be kept in mind to clinical practice that in chronic cases, tophi may localized in atypical regions other than classical localizations, and tophus may lead to joint destruction due to delayed treatment.

Özet

Gut hastalığı genellikle 40 yaş üzeri erkeklerde görülen, hiperürisemiye bağlı olarak dokularda biriken monosodyum ürat monohidratkristallerinin tetiklediği enflamatuvar bir hastalıktır. Yeterince tedavi edilmeyen hastalarda kronik destrüktif poliartrit ve tofüslerle seyredenkronik gut artriti gelişebilmektedir. Tofüsler sıklıkla el-ayak parmaklarında, olekranon bursada, prepatellar bursada, kulak heliksinde veaşil tendonunda gözlenir. Bizim olgumuzda ise el-ayak eklemleri, kulak heliksi ve olekranon bursadaki tofüslerin yanında bilateral lomberparavertebral kaslar ve sol servikal paravertebral kaslarda tofüsler mevcuttu. Kolşisin 1 mg/gün ve allopurinol 300 mg/gün başlanan hastadaaltıncı aydaki kontrolünde eklem ağrıları düzelmiş, kulak heliksindeki tofüsü tamamen kaybolmuştu. Sonuç olarak, kronik olgularda tofüslerinklasik yerleşim yerleri dışında atipik bölgelerde yerleşebileceği ve tedavide gecikme sebebiyle oluşacak tofüslerin eklem harabiyetine yolaçabileceği klinik pratikte akılda tutulmalıdır.

🔖

Cite This Article

KAYA, S. S., OKCU, M. (2022). A Case of Chronic Gouty Arthritis with Atypical Localized Tophi. Türk Osteoporoz Dergisi, Cilt: 24 - Sayı: 1, 26–28. https://ajindex.com/articles/639702

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (7)

  1. Sundy JS. Progress in the pharmacotherapy of gout. Curr Opin Rheumatol 2010;22:188-93.
  2. Rider TG, Jordan KM. The modern management of gout. Rheumatology (Oxford) 2010;49:5-14.
  3. Khanna D, Fitzgerald JD, Khanna PP, Bae S, Singh, MK, Neogi T, et al. 2012 American College of Rheumatology guidelines for management of gout. Part 1: systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia. Arthritis Care Res (Hoboken) 2012;64:1431-46.
  4. Janssens HJ, Janssen M, van de Lisdonk, EH, van Riel PL, van Weel C. Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial. Lancet 2008;371:1854-60.
  5. Robinson PC, Dalbeth N. Advances in pharmacotherapy for the treatment of gout. Expert Opin Pharmacother 2015;16:533-46.
  6. Kotake S, Nanke Y. Spinal Tophaceous Gout. Intern Med 2012;51:237-8.
  7. Richette P, Bardin T. Gout. Lancet 2010;375:318-28. Doherty M. New insights into the epidemiology of gout. Rheumatology 2009:48(Suppl 2):2-8. Terkeltaub R. Crystal deposition diseaes. In: Goldman L, Ausiello D, editors. Cecil Medicine. Philadelphia: Saunders Elsevier; 2008. p. 2069-78. Mandell BF. Clinical manifestations of hyperuricemia and gout. Cleve Clin J Med 2008;75(Suppl 5):5-8.